

**EKF Diagnostics Holdings plc**  
("EKF" or the "Company")

**Result of AGM and Voting Results**

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that at its Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

The voting results of the AGM were as follows:

Resolution	For		Against		Withheld
	Votes	%	Votes	%	Votes
1	318,641,499	99.98%	75,000	0.02%	1,500
2	310,062,339	99.96%	133,585	0.04%	8,522,075
3	318,568,840	99.95%	147,659	0.05%	1,500
4	259,503,846	99.73%	695,153	0.27%	58,519,000
5	318,251,767	99.85%	464,104	0.15%	2,128
6	318,501,187	99.93%	214,684	0.07%	2,128
7	318,588,459	99.96%	128,040	0.04%	1,500
8	314,009,185	98.52%	4,707,814	1.48%	1,000
9	318,621,568	99.97%	95,431	0.03%	1,000
10*	318,586,027	99.96%	130,472	0.04%	1,500
11*	316,611,563	99.34%	2,102,808	0.66%	3,628
12*	267,450,726	83.92%	51,263,645	16.08%	3,628
13	261,555,232	84.17%	49,194,657	15.83%	7,968,110

**EKF Diagnostics Holdings plc**  
Julian Baines, Executive Chair  
Gavin Jones, Chief Executive Officer

[www.ekfdiagnostics.com](http://www.ekfdiagnostics.com)  
via Walbrook PR

**Tel: +44 (0)20 7496 3000**

**Singer Capital Markets (Nominated Adviser & Broker)**  
Phil Davies / Oliver Platts

**Walbrook PR Limited**  
Paul McManus / Alice Woodings

**Tel: +44 (0)20 7933 8780 or [ekf@walbrookpr.com](mailto:ekf@walbrookpr.com)**  
**Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654**



**About EKF Diagnostics Holdings plc ([www.ekfdiagnostics.com](http://www.ekfdiagnostics.com))**

EKF is an AIM-listed global diagnostics business focussed on:

- **Point-of-Care** analysers in the key areas of Hematology and Diabetes
- **Life Sciences** services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGPKKBNNBKDFPB